Emergent BioSolutions (NYSE:EBS – Get Free Report) had its price target hoisted by investment analysts at Benchmark from $5.00 to $8.00 in a research note issued on Thursday, Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Benchmark’s price target points to a potential upside of 32.01% from the company’s previous close.
Emergent BioSolutions Price Performance
Shares of NYSE:EBS opened at $6.06 on Thursday. The firm’s 50 day moving average is $4.34 and its two-hundred day moving average is $3.00. The firm has a market capitalization of $317.54 million, a P/E ratio of -0.55 and a beta of 1.64. The company has a current ratio of 1.08, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67. Emergent BioSolutions has a 52 week low of $1.42 and a 52 week high of $9.96.
Emergent BioSolutions (NYSE:EBS – Get Free Report) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of ($3.65) by $4.24. Emergent BioSolutions had a negative return on equity of 18.53% and a negative net margin of 47.68%. The firm had revenue of $300.40 million for the quarter. During the same quarter in the prior year, the business earned ($3.17) earnings per share. Analysts anticipate that Emergent BioSolutions will post -1.98 earnings per share for the current year.
Insider Activity at Emergent BioSolutions
Institutional Trading of Emergent BioSolutions
A number of hedge funds and other institutional investors have recently modified their holdings of EBS. Charles Schwab Investment Management Inc. boosted its stake in Emergent BioSolutions by 84.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,873,984 shares of the biopharmaceutical company’s stock valued at $6,898,000 after buying an additional 1,312,934 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in Emergent BioSolutions by 356.2% in the 4th quarter. Assenagon Asset Management S.A. now owns 834,372 shares of the biopharmaceutical company’s stock valued at $2,002,000 after acquiring an additional 651,480 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Emergent BioSolutions by 14.7% during the 1st quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock valued at $8,631,000 after purchasing an additional 436,911 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Emergent BioSolutions in the 3rd quarter worth approximately $712,000. Finally, Cetera Advisors LLC bought a new stake in shares of Emergent BioSolutions in the 1st quarter worth approximately $428,000. Institutional investors own 78.40% of the company’s stock.
Emergent BioSolutions Company Profile
Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.
Further Reading
- Five stocks we like better than Emergent BioSolutions
- Best Stocks Under $10.00
- Signet Jewelers Stock Poised for Rebound After Earnings Drop
- How Investors Can Find the Best Cheap Dividend Stocks
- Airship AI Lands New Contract: Stock Soars 16% and More to Come
- Investing in Construction Stocks
- Restoration Hardware Stock: Should You Buy After Earnings Drop?
Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.